Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Farmabrasilis
Street 1: .
Street 2: .
City: Campinas
Province: São Paulo
Post Code:
Country: Brazil
Phone: *
Email: .
Web Site: http://www.farmabrasilis.org

Focal Point Contact Information

Salutation: Dr.
First Name: Iseu
Last Name: Nunes
Title: CEO
Email: .
Phone:  

Alternate Focal Point Contact Information

Salutation: Dr
First Name: Iseu
Last Name: Nunes
Title:  
Email: .
Phone: .

General Information

Board Constituency: Developing Country NGO
Organization Type - Primary: Non-Governmental Organization
Organization Type - Secondary: Other Non-Governmental Organization (NGO)
Is your organization legally registered in your country: Yes
Organization Reach: International
Organization Description:
PROFILE:

Farmabrasilis is a non-governmental, non-profit research network bringing together Brazilian, Chilean, American and European scientists and people devoted to the research and development of new medicines and technologies for the benefit of economically disadvantaged populations and individuals affected by neglected diseases.

Since 1987, Farmabrasilis has been developing innovative and efficient medicaments for infectious diseases and cancer.

MISSION:

Research and development of new medicaments and technologies for the benefit of economically disadvantaged populations and individuals affected by neglected diseases.

GOALS:

1- Build an open model for research and development of pharmaceuticals,

2- Create and disseminate new strategies for research and development of medicines and related technologies in favour of economically disadvantaged populations,

3- Expand and ensure the development of technologies to support translational research,

4-Transfer the production technology of our products free of charge for use by neglected diseases and populations.


PRODUCT LICENCING POLICY:

When appropriate, our medicines can be licensed without royalties in order to allow their use by populations that would otherwise be unable to purchase them.

PARTNERSHIPS AND ALLIANCES

Farmabrasilis is seeking collaborators and partners for the production and distribution of new medicaments for the benefit of neglected diseases and populations.

We are also sharing with the scientific community and instituitions devoted to neglected diseases and populations our new medicines.

Furthermore, we are open to forging alliances with individual researchers, research networks and other scientific institutions to pursue new research lines, including TB.

If these are your interests, contact us.
 
Total number of staff in your organization: 6 - 10
Number of full-time staff who are directly involved with TB: 6 - 10
Number of part-time staff who are directly involved with TB: 1 - 5
Number of volunteers who are directly involved with TB: 11 - 25
 
What is your organization's annual budget (USD) dedicated to TB? $100,001-$500,000
How did you hear about the Stop TB Partnership: Other partners
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Network with other partners
 
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
.
 

Geographical Reach

Which country is your headquarters located in: Brazil
Which WHO region is the main focus of your work: American
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Brazil

Specializations

Advocacy
Funding, including innovative and optimized approach to funding TB Care
Research and Development
Technical Assistance

Specializations in Countries

Research and Development Brazil

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

TB-HIV:
A PLAN TO FIGHT HIV/TB :
One of the most important goals of our organization is to contribute to the fight against TB, leishmaniaisis, malaria and other infectious diseases, particularly in developing countries, where the problem is compounded by the spread of HIV-AIDS.

Focusing on this goal, and as a StopTB partner, we introduce a proposal to fight HIV/Tb, based on the following three points:
- A new product
- A new therapeutic approach
- A scheme to allow its universal use, in particular by disadvantaged population.

The new product is the immunomodulator P-MAPA which has been under development for the last 17 years by Farmabrasilis. It has already passed preclinical and pilot clinical trials.
The new therapeutic approach is the reestablishment of immunocompetence of patients with infectious diseases, including those co-infected with HIV, by adjuvant immunotherapy with P-MAPA.
A key aspect of this proposal is the scheme for universal use. P-MAPA is an affordable immunomodulator, obtained by a classical fungal fermentation process.No high technology needs to be involved. Farmabrasilis has developed a large-scale, low-cost production technology of P-MAPA, and is in a position to transfer the know-how to its partners, even in countries with no tradition of pharmaceutical manufacture.Furthermore, our product licensing policy includes the possibility of royalty-exempt transference of technology in the case of neglected diseases and economically disadvantaged populations.

For additional information : www.farmabrasilis.org

and

http://www.farmabrasilis.org.br/pesquisa_desenvolvimento_interna.php?idioma=eng&id=255


New TB Drugs:
For more information see:
http://www.infectagentscancer.com/content/7/1/14/abstract

Declaration

Declaration of interests:
As a duly authorized representative of my organization, I declare that no real, potential, or apparent conflict of interests with persons and organizations is known to me - Iseu Nunes


Application date: February 23, 2009
Last updated: June 15, 2017